More Conneqt Health Limited news
Conneqt Health LimitedASX: CQT

AtCors XCEL device clinically validated in 3rd party study

Jan 23, 2018 at 1:09 AM EST · Issued by Conneqt Health Limited

Filed with ASX · Jan 23, 2018 at 1:09 AM EST

On 6ix: 6ix.com/news/atcors-xcel-device-clinically-validated-in-3rd-party-study

Conneqt Health Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Conneqt Health Limited on 6ix

Story so far

  • Positive Novartis drug trial using SphygmoCor XCELJan 23, 2017

Earlier from Conneqt Health

  • AtCor and PhysioAge Systems announce supply agreementJan 10, 2018
  • AtCor secures $1.0 million new pharmaceutical trial contractDec 14, 2017
  • AtCor appoints Craig Cooper as CEONov 30, 2017
  • Chairmans address to 2017 AGMNov 29, 2017
  • Tax RefundOct 30, 2017

Later from Conneqt Health

  • AtCor Announces First Steps in Major Strategic RepositioningMar 14, 2018
  • Oversubscribed Capital Raising to Fast Track New StrategyApr 22, 2018
  • Underwritten Rights Issue Prospectus Lodged with ASICApr 23, 2018
  • Blumio Wearable Cardio Trial with Macquarie UniversityMay 20, 2018
  • AtCor Announces Wearable Trial with Macquarie UniversityMay 21, 2018
All Conneqt Health news releases↗

Follow Conneqt Health into a list and get an email when it puts out news.

Follow Conneqt Health
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer